Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort
Abdullahi A., Kida IM., Maina UA., Ibrahim AH., Mshelia J., Wisso H., Adamu A., Onyemata JE., Edun M., Yusuph H., Aliyu SH., Charurat M., Abimiku A., Abeler-Dorner L., Fraser C., Bonsall D., Abeler-Dörner L., Ayles H., Bonsall D., Bowden R., Calvez V., Essex M., Fidler S., Fraser C., Grabowski K., Golubchik T., Gupta R., Hayes R., Herbeck J., Kagaayi J., Kaleebu P., Lingappa J., Moyo S., Novitsky V., Ndung'u T., Pillay D., Quinn T., Rambaut A., Ratmann O., Seeley J., Ssemwanga D., Tanser F., Wawer M., Cohen M., D'Oliveira T., Dennis A., Essex M., Fidler S., Frampton D., Fraser C., Golubchik T., Hayes R., Herbeck J., Hoppe A., Kaleebu P., Kellam P., Kityo C., Leigh-Brown A., Lingappa J., Novitsky V., Paton N., Pillay D., Quinn T., Ratmann O., Ssemwanga D., Tanser F., Wawer M., Kemp SA., Gupta RK.
Abstract Background Due to the high prevalence of resistance to NNRTI-based ART since 2018, consolidated recommendations from the WHO have indicated dolutegravir as the preferred drug of choice for HIV treatment globally. There is a paucity of resistance outcome data from HIV-1 non-B subtypes circulating across West Africa. Aims We characterized the mutational profiles of persons living with HIV from a cross-sectional cohort in North-East Nigeria failing a dolutegravir-based ART regimen. Methods WGS of plasma samples collected from 61 HIV-1-infected participants following virological failure of dolutegravir-based ART were sequenced using the Illumina platform. Sequencing was successfully completed for samples from 55 participants. Following quality control, 33 full genomes were analysed from participants with a median age of 40 years and median time on ART of 9 years. HIV-1 subtyping was performed using SNAPPy. Results Most participants had mutational profiles reflective of exposure to previous first- and second-line ART regimens comprised NRTIs and NNRTIs. More than half of participants had one or more drug resistance-associated mutations (DRMs) affecting susceptibility to NRTIs (17/33; 52%) and NNRTIs (24/33; 73%). Almost a quarter of participants (8/33; 24.4%) had one or more DRMs affecting tenofovir susceptibility. Only one participant, infected with HIV-1 subtype G, had evidence of DRMs affecting dolutegravir susceptibility—this was characterized by the T66A, G118R, E138K and R263K mutations. Conclusions This study found a low prevalence of resistance to dolutegravir; the data are therefore supportive of the continual rollout of dolutegravir as the primary first-line regimen for ART-naive participants and the preferred switch to second-line ART across the region. However, population-level, longer-term data collection on dolutegravir outcomes are required to further guide implementation and policy action across the region.